Clinical Trials Browser

Unknown × Cisplatin × Thoracic × Clear all

NCT06208033 2024-01-17

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

Phase EARLY_PHASE1 Unknown

EGFR Positive Non-small Cell Lung Cancer

NCT05092412 2024-01-12

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

Phase 2 Unknown

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06110663 2023-11-01

A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03380468 2023-07-20

ECTOP-1004

Phase 2/3 Unknown

Adenocarcinoma of Lung, Lung Neoplasms

NCT00632853 2023-06-12

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Phase 3 Unknown

731 enrolled 11 charts

Lung Neoplasms

NCT03991403 2023-04-03

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04646837 2023-03-29

Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00526396 2023-03-24

STAD-1

Phase 3 Unknown

Small Cell Lung Carcinoma

NCT01405586 2023-03-24

MILES-3

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01656551 2023-03-24

MILES-4

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05746598 2023-02-28

Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer Patients

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Kidney Diseases, Cardiotoxicity

NCT03574402 2022-12-06

TRUMP

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02436733 2022-11-07

Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05574998 2022-10-12

FTANLCNDG

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05312840 2022-04-06

Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Cindilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer

Phase 4 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05245994 2022-02-18

An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

Phase 2 Unknown

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02743923 2021-12-21

Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05034133 2021-09-05

Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer

Phase 2 Unknown

Limited Stage Small Cell Lung Cancer

NCT04586465 2021-08-24

DYNAPET

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04465942 2021-08-23

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

Carcinoma, Non-Small-Cell Lung

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04982549 2021-08-06

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Phase 2 Unknown

Unresectable Stage III NSCLC

NCT04865705 2021-04-29

Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02667743 2021-03-17

Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04768075 2021-02-24

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Phase 2/3 Unknown

Nonsquamous Non-small Cell Lung Cancer

NCT04490421 2021-02-08

Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.

Phase 3 Unknown

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04733521 2021-02-02

A Phase 1/2 Study of SC-43 in Combination With Cisplatin

Phase 1/2 Unknown

GastrointestinalThoracic

Advanced Non-small-cell Lung Cancer

NCT02337712 2021-01-27

Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung Cancer

Phase 2 Unknown

Small Cell Lung Carcinoma

NCT04646824 2020-12-02

Almonertinib With Chemotherapy in mEGFR NSCLC

Phase 2 Unknown

Non-Small Cell Lung Cancer Metastatic

NCT02977169 2020-11-13

To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04543890 2020-09-10

CTV

Phase 2 Unknown

Small Cell Lung Cancer Limited Stage

NCT04470076 2020-07-14

Neoafa

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04455594 2020-07-02

ANSWER

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Carcinoma, Non-Small-Cell Lung

NCT04363255 2020-04-28

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

Phase 2 Unknown

Small Cell Lung Carcinoma

NCT03706287 2020-04-06

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02076477 2020-03-17

OITROLC

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03585998 2020-03-02

Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer

Phase 2 Unknown

Small Cell Lung Carcinoma

NCT02996214 2020-02-13

LIPUSU

Phase 4 Unknown

Squamous Non-small-cell Lung Cancer

NCT02725918 2020-02-12

Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03613597 2020-02-05

Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer

Phase 2 Unknown

Small Cell Lung Carcinoma

NCT04189094 2019-12-06

Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC

Phase 2 Unknown

Lung Neoplasms

NCT03062800 2019-06-05

Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03374280 2019-03-28

Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02657460 2019-02-26

Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion

Phase 2 Unknown

Pleural Effusion, Malignant

NCT02433626 2019-02-01

COTI2-101

Phase 1 Unknown

GastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03781869 2018-12-20

Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer

Phase 2 Unknown

Small Cell Lung Carcinoma

NCT03671538 2018-09-17

Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin

Phase NA Unknown

Non-squamous Non-small Cell Lung Cancer

NCT01407822 2018-09-11

EMERGING

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms